Recent 8-K filings for AVBP

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 11, 2026 20:43 UTC other_material item 8.01item 9.01

  ArriVent BioPharma expands at-the-market equity program by up to $250M

• May 11, 2026 20:05 UTC earnings item 2.02item 9.01

  ArriVent Q1 net loss $43.3M; cash $326.4M; Phase 3 firmonertinib data mid-2026

source · AVBP on sec.gov